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Abstract: Continuous flow processes have recently emerged as a powerful technology for 
performing chemical transformations since they ensure some advantages over traditional 
batch procedures. In this work, the use of commercially available and affordable PEEK 
(Polyetheretherketone) and PTFE (Polytetrafluoroethylene) HPLC (High Performance Liquid 
Chromatography) tubing as microreactors was exploited to perform organic reactions under 
continuous flow conditions, as an alternative to the commercial traditional glass 
microreactors. The wide availability of tubing with different sizes allowed quickly running 
small-scale preliminary screenings, in order to optimize the reaction parameters, and then to 
realize under the best experimental conditions a reaction scale up for preparative purposes. 
The gram production of some Active Pharmaceutical Ingredients (APIs) such as (S)-Pregabalin 
and (S)-Warfarin was accomplished in short reaction time with high enantioselectivity, in an 
experimentally very simple procedure. 
Keywords: asymmetric synthesis; organocatalysis; flow chemistry; microreactors; active 
pharmaceutical ingredients; PEEK tubing 
 
1. Introduction 
Continuous flow processes have recently emerged as a powerful technology for performing chemical 
transformations since they ensure some advantages over traditional batch procedures, for example, safer 
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handling of hazardous materials, more efficient heat and mass transfers and precise control of reaction 
parameters by inline monitoring may be accomplished [1–5]. Many research groups have focused 
attention onto this field favoring a gap closure between academia and industry [6–13]. An example of 
innovative synthetic procedure that could be applied in pharmaceutical industry was reported by 
Seeberger and coworkers. They recently published the continuous flow synthesis of five Active 
Pharmaceutical Ingredients (APIs) (Rolipram, Pregabalin, Phenibut, Baclofen, and Gabapentin) in 
racemic form. The flow system used to produce all these APIs is based on different modular synthetic 
platforms, operating under a wide range of reaction conditions. By following different linking pathways 
of the modules, the synthetic platform gives access to several small molecule drugs in multigrams scale 
without requiring intermediate purification [14]. However, racemic mixtures of chiral APIs need to be 
resolved, since usually only one enantiomer is more active or effective. For this reason, the development 
of an enantioselective synthesis of chiral APIs would be highly desirable. 
Asymmetric organocatalysis represents a powerful strategy for performing stereoselective 
transformations ensuring high levels of enantioselectivity [15,16]. The extremely fast growth of  
metal-free catalytic methodologies and novel organocatalytic stereoselective transformations has opened 
new avenues in the synthesis of complex chiral molecules, and has offered unique possibilities to develop 
more sustainable processes [17]. Since organocatalysis involves simple organic molecules as catalysts, 
the contamination of final products with heavy metals is intrinsically avoided; thus, the combination of 
organocatalysis with flow chemistry would represent an effective methodology for the synthesis in 
continuo of enantiomerically pure APIs. 
The use of chiral organocatalysts under flow conditions is, however, still underdeveloped. In the last 
few years, the use of organocatalytic chiral reactors has received considerable attention, leading to the 
development of different supported chiral metal-free catalysts employed in continuous-flow 
processes [18–21]. Also our group contributed to this field and realized packed-bed and monolithic 
reactors containing solid supported chiral catalysts such as cinchona derivates [22] and chiral 
imidazolidinones [23–25]. On the other hand, homogeneous organocatalytic reactions performed under 
continuous flow conditions, for example in microreactors, are much less explored, the very few studies 
being almost exclusively limited to proline derivatives [26–29]. Recently, we have reported the use of a 
chiral bifunctional catalyst in glass microreactors, exploiting the potentiality of microfluidic technique 
to successfully accomplish enantioselective Michael type additions reactions [30]. Commercially available 
glass microreactors have extensively been used for performing continuous flow organic transformations. 
Due to the narrow size of the channels (internal diameter less than 1 mm), flow microreactors feature 
extremely efficient heat and mass transfers and allow running chemical reactions very rapidly, with 
residence times of few minutes only. 
In this work, we wish to demonstrate the possibility of using simple HPLC connections (PEEK or 
PTFE tubing, inner diameter 0.1–0.5 mm) instead of traditional glass microreactors to perform 
stereoselective organocatalyzed continuous flow reactions. In this context, the stereoselective synthesis 
in continuo of (S)-Pregabalin intermediate and (S)-Warfarin through two organocatalytic strategies has 
been reported. 
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2. Results and Discussion 
In a preliminary experiment, we compared the use of PEEK microreactor II with the use of a 
commercially available glass microreactor I (Figure 1), recently used by our group in catalytic Michael 
reactions. In our previous work [30], the addition of acetylacetone 2 to nitrostyrene 1 catalyzed by 
Takemoto thiourea 3 [31,32] (Scheme 1) was performed in a Chemtrix Labtrix® Start Standard platform 
system (Glass microreactor I, Chemtrix SOR 3223, channel width 0.3 mm and channel depth 0.12 mm, 
total volume 10 μL, 70 °C and 5 min residence time) to give the corresponding product 4 in 91% yield 
and 80% ee. 
 
(a) (b) 
Figure 1. Examples of (a) glass microreactor I and (b) PEEK (Polyetheretherketone) 
microreactor II. 
 
Scheme 1. The addition of acetylacetone 2 to nitrostyrene 1 catalyzed by Takemoto thiourea 3. 
In this work, the glass microreactor was replaced with a commercially available PEEK tubing 
designed for HPLC applications (PEEK microreactor II, inner diameter 0.127 mm, length 79 cm, total 
volume 10 μL) that was coiled in a bundle and immersed in a preheated oil bath. A Chemix Fusion 100 
syringe pump equipped with two Hamilton gastight 1 mL syringes was used to feed the reagents into the 
microreactor through a T-junction (Syringe A: nitrostyrene 1; Syringe B: acetylacetone 2 and Takemoto 
thiourea 3). 
Preliminary results are reported in Table 1. 
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Table 1. Comparison between glass microreactor I and PEEK (Polyetheretherketone) 
microreactor II. 





Conversion (%) b ee (%) c
1 Glass microreactor I RT 2 5 32 47 
2 Glass microreactor I 70 2 5 91 80 
3 PEEK microreactor II RT 2 5 76 80 
4 PEEK microreactor II 65 2 5 99 75 
5 PEEK microreactor II 65 4 2.5 99 77 
a The total flow rate is given by the sum of the flow rates of the two syringes  that feed the microreactor with 
the same rate; b Monitored by HPLC using phenanthrene as internal standard; c Determined by HPLC on 
chiral stationary phase (see ESI for details). 
Gratifying, product 4 was obtained in 76% yield and 80% ee even at room temperature when PEEK 
microreactor II was employed (Entry 3 vs. Entry 2). Better yields were obtained when the temperature 
was increased to 65 °C, where a complete conversion was observed without loss of enantioselectivity 
(Entry 4). Even halving the residence time (Entry 5) allowed obtaining comparable yield and ee. 
On the basis of these satisfactory results, we decided to explore the use of PEEK microreactor 
technology to perform organocatalyzed stereoselective synthesis of APIs. In particular, the stereoselective 
addition of diethylmalonate 6 to aliphatic nitroalkene 5 catalyzed by Takemoto thiourea 3 for the 
synthesis of (S)-Pregabalin intermediate 7 is reported in Section 2.1; the use of chiral primary amine 10 
derived from cinchona alkaloids for the continuous flow stereoselective synthesis of (S)-Warfarin 11 is 
highlighted in Section 2.2. 
2.1. Chiral Thiourea Organocatalyst: Continuous Flow Synthesis of (S)-Pregabalin Intermediate 
(S)-Pregabalin, marketed under the trade name Lyrica, is a wide-administered anticonvulsant and 
antiepileptic drug. As previously reported in the literature, the stereoselective nucleophilic addition of 
diethylmalonate 6 to nitroalkene 5 promoted by chiral thiourea 3 could be considered a suitable strategy 
for the preparation of chiral intermediate 7 [33,34]. Reduction of the nitro moiety followed by hydrolysis 
and decarboxylation, affords (S)-Pregabalin (Scheme 2). 
In our initial experiments, we employed PEEK microreactor II with a total volume of 10 μL in order 
to demonstrate the compatibility of the organocatalytic methodology with continuous flow processes. A 
syringe pump equipped with two syringes was used to feed microreactor II with the reagents through a 
T-junction. Conversion and enantiomeric excess were calculated through high-performance liquid 
chromatography (HPLC) analysis using phenantrene as an internal standard and with preliminary 
calibration experiments (Syringe A: nitroalkene 5 and internal standard; Syringe B: diethylmalonate 6 
and Takemoto thiourea 3). Microreactor II was coiled in a bundle and immersed in a preheated oil bath. 
After a screening of reagent concentrations and reaction temperatures (Table 2), it was found that the 
product was formed in 36% conversion and 79% enantiomeric excess using a residence time of 10 min 
(Entry 8, Table 2). It is worth noting that the same reaction performed in a single batch afforded product 7 
in 88% yield and 81% ee after 48 h at room temperature (literature data [31]); in our hands, product 7 
was recovered in >98% yield and 77% ee after 48 h at 60 °C. To further compare the flow process to the 
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batch process, we performed the same reaction at 70 °C and stopped it after 10 min reaction (residence 
time under continuous flow conditions); product 7 was recovered in 8% yield only (75% ee). 
 
Scheme 2. Synthesis of (S)-Pregabalin in flow. 
Table 2. Preliminary results for the synthesis of (S)-Pregabalin intermediate 7: 10 μL PEEK 
microreactor II, flow rate 1 μL/min, residence time 10 min. 
 
Entry 5 [M] a 6 [M] a T (°C) Conversion (%) b ee (%) c 
1 0.5 1.0 25 0 - 
2 0.5  1.0 65 35 77 
3 0.5  1.0 100 28 71 
4 0.5  2.0 100 32 69 
5 0.5  2.0 120 22 59 
6 0.5  neat 105 19 76 
7 0.5  neat 135 19 72 
8 1.0 3.3 60 36 79 
9 1.0 3.3 80 34 76 
10 1.0 neat 60 25 77 
11 1.0 neat 85 24 73 
a Molarity values correspond to the effective concentration inside the microreactor; b Monitored by HPLC using 
phenanthrene as an internal standard; c Determined by HPLC on chiral stationary phase (see ESI for details). 
Attempts to scale up the reaction by increasing the size of the microreactor were conducted using 
PTFE microreactor III (inner diameter 0.58 mm, length 189 cm, total volume 500 μL) (Scheme 3). By 
performing the reaction under the previously optimized reaction conditions, we were able to obtain 
product 7 in 40% conversion and 79% ee (Entry 3, Table 3), thus confirming the results obtained using 
microreactor II (Table 3). When the residence time was lowered from 10 to 5 and 2 min (by increasing 
the flow rate), conversions and ee remained unchanged (Entries 4 and 5); no improvements in terms of 
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conversion were observed when the temperature was increased to 80 °C (Entry 6). We then decided to 
performed a gram-scale synthesis of (S)-Pregabalin intermediate 7: under the best reaction conditions 
(60 °C, 2 min residence time) we were able to produce 1 g of 7 in 81% ee, in one hour only using a very 
simple flow apparatus (Scheme 3). 
 
Scheme 3. Gram-scale synthesis of 7 in 500 μL microreactor III. 
Table 3. 500 μL PTFE microreactor III, screening of different flow rates. 
 
Entry Total Flow Rate (μL/min) a Residence Time 
(min) 
T (°C) Conversion (%) b ee (%) c 
1 2 30 60 55 76 
2 4 15 60 56 76 
3 6 10 60 40 79 
4 12 5 60 37 79 
5 30 2 60 37 80 
6 30 2 80 13 77 
a The total flow rate is given by the sum of the flow rates of the two syringe pumps that feed the microreactor 
with the same rate; b Monitored by HPLC using phenanthrene as an internal standard; c Determined by HPLC 
on chiral stationary phase (see ESI for details). 
2.2. Chiral Primary Amine Organocatalyst: Continuous Flow Synthesis of (S)-Warfarin 
(S)-Warfarin, known with the brand name of Coumadin or Jantoves, is an oral anticoagulant, a drug 
that inhibits the clotting of blood. Since it can be prepared through different organocatalytic 
strategies [35,36], we identified the nucleophilic addition of 4-hydroxy-coumarin 8 to benzalacetone 9 
catalyzed by cinchona-derived primary amine 10 [37] as the most straightforward methodology 
compatible with flow microreactors. 
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A solvent screening for the homogeneous reaction in batch was first performed in order to select the 
best reaction medium to provide high ee (see Table S1 of ESI for further details). It was found that 
dioxane was the best solvent for the addition of 4-hydroxy-coumarin 8 to benzalacetone 9 promoted by 
cinchona-derived primary amine 10 (10 mol%) in the presence of trifluoroacetic acid as a co-catalyst, 
that afforded product 11 in 99% yield and 96% ee after 24 h at 30 °C (Entry 6, Table S1). 
In order to optimize the reaction conditions in flow, we employed PEEK microreactor II; the flow 
apparatus was settled as illustrated in Scheme 4. A syringe pump equipped with two syringes was used 
to feed microreactor II with the reagents through a T-junction (Syringe A: coumarin 8; Syringe B: 
benzalacetone 9, chiral catalyst 10 and trifluoroacetic acid). Microreactor II was coiled in a bundle and 
immersed in a preheated oil bath. Conversion was determined by 1H-NMR spectroscopy of the crude 
mixture while enantiomeric excess through HPLC on chiral stationary phase. 
 
Scheme 4. Synthesis of (S)-Warfarin in flow. 
Different combinations of flow rates and reaction temperatures were investigated (Table 4). It should 
be noted that, due to low solubility profile of coumarin 8, it was necessary to work under high dilution 
conditions (0.05 M) in order to prevent coumarin precipitation in the syringe. As shown in Table 4, the 
conversion increased with increasing temperature, while the ee remained constantly high (>90%). 
Optimum reaction conditions were found to be 75 °C and 1 μL/min flow rate (corresponding to 10 min 
residence time), which lead to the formation of the desired product 11 with 61% conversion and 93% ee 
(Entry 5, Table 4). 
With the aim to scale up the reaction we tried to synthetize compound 11 using the 500 μL PTFE 
microreactor III under the best reaction conditions previously found. However, the reaction conditions 
settled in microreactor II showed to be not reproducible: by performing the reaction in dioxane at 75 °C 
with a residence time of 10 min (obtained with 50 μL/min flow rate), the product was isolated in 95% 
ee but in 29% yield only (Entry 1, Table 5). An increase of the residence time did not have a beneficial 
effect in terms of both yield (20% yield) and enantioselectivity (Entries 2 and 3, Table 5). 
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Table 4. Screening of flow rate and temperature for 10 μL PEEK microreactor II. 
 
Entry Total Flow Rate (μL/min) a Residence Time (min) T (°C) Conversion (%) b ee (%) c
1 2 5 30 15 95 
2 1 10 40 38 95 
3 1 10 50 51 95 
4 1 10 60 55 95 
5 1 10 75 61 93 
6 1 10 90 65 90 
a The total flow rate is given by the sum of the flow rates of the two syringes that feed the microreactor with 
the same rate; b Monitored by NMR on the crude mixture; c Determined by HPLC on chiral stationary phase 
(see ESI for details). 
Table 5. Synthesis of 11 in 500 μL PTFE microreactor III. 
 
Entry Total Flow Rate (μL/min) a Residence Time (min) Yield (%) b ee (%) c
1 50 10 29 95 
2 17 30 20 86 
3 8 60 20 81 
a The total flow rate is given by the sum of the flow rates of the two syringes that feed the microreactor with 
the same rate; b Isolated yields after flash column chromatography on silica gel; c Determined by HPLC on 
chiral stationary phase (see ESI for details). 
It is possible that different microfluidic properties of a 0.58 mm inner diameter tubing (PTFE 
microreactor III) with respect to the 0.127 mm inner diameter tubing (PEEK microreactor II) could 
account for the failure of the scale up process. We then decided to explore the “numbering up” (or “scale 
out”) technique, which consists of connecting several microreactors of the same dimension in parallel. 
As depicted in Scheme 5, by using a stainless-steel splitter (2 inlet and 4 outlet), four PEEK 
microreactors II were connected in parallel and immersed in a preheated oil bath. A 0.05 M solution of 
coumarin 8 and a 0.1 M solution of benzalacetone 9 together with catalyst 10 and trifluoroacetic acid, 
were fluxed into the splitter with a flow rate of 4 μL/min (10 min residence time in each microreactor); 
the microreactors were kept at 75 °C and the reactors outcome was collected into a vial. Product 11 was 
isolated in 36% yield and 91% ee. Attempts to collect the four reaction outcomes separately showed that 
the four microreactors afforded slightly different yields. At this stage we believe that the mixing in the 
splitter is not efficient and it may account for the lower yield; further studies and optimization works on 
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the differently components of the device are currently going on. In addition, the necessity of working 
under dilution conditions, due to the low solubility of coumarin, prevents the possibility to produce a 
large amount of the desired product in a short reaction time.  
 
Scheme 5. Scale-out process: 4 × 10 μL PEEK microreactors II. 
Despite the unsatisfactory results obtained in the Warfarin scale up process, few issues deserve a 
comment: by using a small-scale reactor it is possible to easily monitor the reaction course (by 1H-NMR 
and/or HPLC analysis) thus establishing the best reaction conditions very quickly by adjusting some 
simple reaction parameters such as temperature and flow rate. After the large-scale reaction, a 
purification step is required in order to separate the desired product from unreacted starting material and 
homogeneous catalyst. This purification step (that is also usually required in the batch process) somehow 
affects the appealing of the continuous-flow process and more efforts are required to circumvent this 
problem. One possible solution could be represented by the use of supported catalysts, that is a  
well-established methodology when meso- or mini-reactors are used [18], but much less exploited in the 
case of microreactors [38]. The combination of an immobilized catalyst and a complete conversion of 
the starting material (or an easy separation of the desired product) could allow a very attractive procedure 
for large-scale production of interesting intermediates. 
3. Experimental 
3.1. General Methods 
Reactions were monitored by analytical thin-layer chromatography (TLC) using silica gel 60 F254  
pre-coated glass plates (0.25 mm thickness) and visualized using UV light. Flash chromatography was 
carried out on silica gel (230–400 mesh). Proton NMR spectra were recorded on spectrometers operating 
at 300 MHz (Bruker Fourier 300 or AMX 300 (Bruker, Billerica, MA, USA)). Proton chemical shifts 
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are reported in ppm (δ) with the solvent reference relative to tetramethylsilane (TMS) employed as the 
internal standard (CDCl3 δ = 7.26 ppm). 
Enantiomeric excess determinations were performed under below reported conditions with Agilent 
1200 or 1100 series HPLC (Agilent, Santa Clara, CA, USA). 
Reagents mixtures were fed to continuous flow reactors using Syringe Pump Chemtrix Chemix 
Fusion 100 (Chemtrix, Geleen, The Netherlands). 
3.2. Materials 
Dry solvents were purchased and stored under nitrogen over molecular sieves (bottles with crown 
caps). Commercial grade reagents and solvents were used without further purifications. Quinine 
(anhydrous, technical grade 98%) and trifluorocetic acid (technical grade 99%) were purchase from 
Sigma-Aldrich (St. Louis, MO, USA) and used without further purifications. 
Trans-nitrostyrene 1 was recrystallized from ethanol, 4-hydroxy-coumarin 8 was recrystallized from 
ethyl acetate, and benzalacetone 9 was recrystallized from hexane. 
Trans-4-methyl-1-nitropent-1-ene [33] was prepared according to published procedure. 
3.3. Microreactors 
Microreactors were prepared using tubing for HPLC connections purchased from Sigma-Aldrich. 
PEEK microreactor II: PEEK tubing, inner diameter 0.127 mm, length 79 cm, total volume 10 µL. 
PTFE microreactor III: PTFE tubing, inner diameter 0.58 mm, length 189 cm, total volume 500 µL. 
3.4. Preparation of Catalysts 3 and 10 
Chiral Takemoto thiourea 3 [31] and 9-amino-9-deoxy-epi-quinine 10 [39] are known compounds 
and were prepared according to published procedures. 
3.5. General Procedure for Continuous Flow Synthesis of Compound 4 Using PEEK Microreactor II 
Syringe A was filled with a mixture of nitrostyrene 1 (2 mmol, 298 mg) dissolved in dry toluene  
(1 mL). Syringe B was loaded with a mixture of chiral thiourea 3 (0.2 mmol, 83 mg) and acetylacetone 2 
(4 mmol, 0.41 mL) dissolved in dry toluene (0.6 mL). Syringes A and B were connected to a syringe 
pump and the reagents were pumped into microreactor II at the desired flow rate (mL/min) and 
temperature. Three reactor volumes were discarded before starting sample collection in order to achieve 
steady-state conditions. Reaction outcome was collected into a vial at room temperature and analyzed 
through 1H-NMR spectroscopy and HPLC in order to determine conversion and enantiomeric excess. 
Compound 4 is known [32]; it was purified by flash column chromatography on silica gel  
(eluent: Hexane/AcOEt = 8/2) to afford a colorless oil. 
TLC Rf = 0.35 (Hexane/AcOEt = 8/2, stained yellow with KMnO4). 
1H-NMR (300 MHz, CDCl3): δ 1.95 (s, 3H), 2.29 (s, 3H), 4.25–4.29 (m, 1H), 4.38 (d, J = 10.7 Hz, 1H), 
4.60–4.69 (m, 2H), 7.09–7.21 (m, 2H), 7.21–7.39 (m, 3H). 
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The enantiomeric excess was determined by HPLC on chiral stationary phase with Daicel Chiralcel  
OD-H column: eluent Hexane/iPrOH = 98/2, flow rate 0.8 mL/min, λ = 280 nm, τminor = 7.9 min,  
τmajor = 10.8 min. 
3.6. General Procedure for Continuous Flow Synthesis of (S)-Pregabalin Intermediate 7 Using PEEK 
Microreactor II 
Syringe A was filled with a mixture of nitroalkene 5 (2 mmol, 258 mg) and phenantrene (1 mmol, 
178 mg) dissolved in dry toluene (1 mL). Syringe B was loaded with a mixture of chiral thiourea 3  
(0.2 mmol, 83 mg) and diethylmalonate 6 (6.6 mmol, 1 mL). Syringes A and B were connected to a 
syringe pump and the reagents were pumped into microreactor II at the desired flow rate (μL/min) at the 
desired temperature. Three reactor volumes were discarded before starting sample collection in  
order to achieve steady-state conditions. Reaction outcome was collected into a vial at room temperature 
and analyzed through 1H-NMR spectroscopy and HPLC in order to determine conversion and 
enantiomeric excess. 
Compound 7 is known [32]; it was purified by flash column chromatography on silica gel  
(eluent: Hexane/AcOEt = 8/2) to afford a colorless oil. 
TLC Rf = 0.26 (Hexane/AcOEt = 8/2, stained yellow with KMnO4). 
1H-NMR (300 MHz, CDCl3): δ 4.70 (dd, J = 13, 5 Hz, 1H), 4.51 (dd, J = 13, 6 Hz, 1H), 4.28–4.20 (m, 
4H), 3.62 (d, J = 5 Hz, 1H), 3.00–2.95 (m, 1H), 1.72.166 (m, 1H), 1.38–1.28 (m, 8H), 0.96–0.92 (m, 6H). 
The enantiomeric excess was determined by HPLC on chiral stationary phase with Daicel Chiralcel 
OD-H column: eluent Hexane/iPrOH = 98/2, flow rate 0.8 mL/min, λ = 280 nm, τminor = 7.9 min, 
τmajor=10.8 min. 
3.7. General Procedure for Continuous Flow Synthesis of (S)-Warfarin 11 Using PEEK Microreactor II 
Syringe A was filled with a mixture of 4-hydroxy-coumarin 8 (0.2 mmol, 32 mg) dissolved in dry 
dioxane (1 mL). Syringe B was loaded with a mixture of chiral primary amine 10 (0.02 mmol, 6 mg), 
trifluoroacetic acid (0.03 mmol, 3 μL) and benzalacetone 9 (0.4 mmol, 58 mg) dissolved in dry dioxane 
(1 mL). Syringes A and B were connected to a syringe pump and the reagents were pumped into 
microreactor II at the desired flow rate (μL/min) and temperature. Three reactor volumes were discarded 
before starting sample collection in order to achieve steady-state conditions. Reaction outcome was 
collected into a vial at room temperature and analyzed through 1H-NMR spectroscopy and HPLC in 
order to determine conversion and enantiomeric excess. 
Compound 11 is known [37]; it was purified by flash column chromatography on silica gel  
(eluent: Hexane/AcOEt = 7/3) to afford a white-off solid. 
TLC Rf = 0.28 (Hexane/AcOEt = 7/3, stained yellow with KMnO4). 
Compound 22 was found to exist in rapid equilibrium with a pseudo-diastereomeric hemiketal form 
in solution. However, the equilibrium is very rapid and therefore no pseudo-diastereomers were observed 
during HPLC analysis using the mixture of hexane/2-propanol containing 0.1% TFA as the eluent. 




1H-NMR (300 MHz, CDCl3): δ 7.98 (dd, 1H), 7.93 (dd, 2.38H), 7.85 (dd, 3.15H), 7.58–7.50  
(m, 7.83H), 7.22–7.4 (m, 54.13H), 4.73 (dd, 1.24H), 4.32 (dd, J = 3.6, 2.87H), 4.12–4.18 (m, 5.53H), 
3.9 (dd, 1.55H), 3.35 (dd, 1.8H), 3.2 (bs, 2.76H), 2.6–2.4 (m, 10.6H), 2.09–2.00 (dd, 5H), 1.76 (s, 12H), 
1.71 (s, 10H). 
The enantiomeric excess was determined by HPLC on chiral stationary phase with Daicel Chiralpack 
AD column: eluent Hexane/iPrOH = 8/2 + 0.1% TFA, flow rate 0.8 mL/min, λ = 280 nm, τminor = 7.8 min, 
τmajor = 19.5 min. 
4. Conclusions 
Readily available and affordable HPLC PEEK tubing were used as microreactors to perform reactions 
under continuous flow conditions. The wide availability of tubing with different sizes allowed quickly 
running small-scale preliminary screenings, in order to optimize the reaction parameters, and then to 
realize under the best experimental conditions a reaction scale up for preparative purposes. The gram 
production of some APIs such as (S)-Pregabalin and (S)-Warfarin were accomplished in short reaction 
times with high enantioselectivity, in an experimentally very simple procedure. 
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